Nafazoline

Naphazoline
* Updated 2011 Dec 14 01:35:00 PM: AHFS data updatedShow more updates
* AHFS data updated
* AHFS data updated
 
General Information
Description:
Vasoconstrictor; an imidazoline-derivative sympathomimetic amine. c
Class:
Class: Vasoconstrictors
Brands:
United States:
* AK-Con®
* Albalon®
* All Clear®
* All Clear® AR
* Clear Eyes®
* ClearEyes® ACR
* Napha A®
* Napha® Forte
* Naphcon®
* Naphcon-A®
* Opcon A®
* VasoClear®
* VasoClear® A
* Vasocon-A®
* Visine A ®
Canada:
* Albalon
* Collyre
* Diopticon
* Naphcon
* Vasocon
* Visine
* Zincfrin
Uses and Efficacy
Uses:
Conjunctival Congestion:
Temporary relief of conjunctival congestion, itching, and minorirritation. a b
Used alone or in fixed combination with antihistamines (e.g., antazoline phosphate, pheniramine maleate) and/or astringents (e.g., zinc sulfate). a e f
Ineffective in the treatment of delayed hypersensitivity reactions such as contact dermatoconjunctivitis. c
Dosage and Administration
Administration:
Ophthalmic Administration:
Apply topically to the conjunctiva. a b c
Avoidcontamination of the dropper tip. a b d
Some manufacturers recommend that contact lenses be removed before administering the ophthalmic solution. a b e
Do not administer discolored or cloudy solutions. b d
Dosage:
Available as naphazoline hydrochloride; dosage expressed in terms of the salt.
Pediatric Patients:
Conjunctival Congestion:
Ophthalmic:
For self-medication in children ≥6 years ofage, 1 or 2 drops of a 0.01–0.05% ophthalmic solution up to 4 times daily or as directed by clinician. c e f
Adults:
Conjunctival Congestion:
Ophthalmic:
1 or 2 drops of a 0.1% ophthalmic solution every 3–4 hours as needed. c d
For self-medication, 1 or 2 drops of a 0.01–0.05% ophthalmic solution up to 4 times daily or as directed by clinician. a c e f
Cautions and Adverse EffectsContraindications:
* Angle-closure glaucoma. c d
* Known hypersensitivity to naphazoline or any ingredient in the formulation. a d
Warnings/Precautions:
Warnings:
MAO Inhibitors:
Concomitant use with MAO inhibitor may result in severe hypertensive crisis. c d
General Precautions:
Sympathomimetic Effects:
Possible headache, hypertension, cardiac irregularities, nervousness, nausea,dizziness, weakness, and sweating. c Use with caution in patients with hypertension, cardiovascular abnormalities, diabetes mellitus, hyperthyroidism, infection, or injury. c d
Overuse:
Possible conjunctival irritation and adverse systemic effects with excessive dosage and/or prolonged or too frequent use. c Possible rebound congestion, characterized by reactive hyperemia. a Avoid prolongeduse. c
Glaucoma:
Use not recommended in patients with glaucoma except under the advice and supervision of a physician. c
Use of Fixed Combinations:
When used in fixed combination with antihistamines (e.g., antazoline phosphate, pheniramine maleate) and/or astringents (e.g., zinc sulfate), consider the cautions, precautions, and contraindications associated with the concomitant drug(s). cSpecific Populations:
Pregnancy:
Category C. d
Lactation:
Not known whether naphazoline is distributed into milk. c Use with caution in nursing women. c d
Pediatric Use:
Safety and efficacy of 0.1% ophthalmic solution not established in infants and children; potential for CNS depression, possibly progressing to coma and hypothermia, especially in infants. c d
0.01–0.05% ophthalmic solutionsnot recommended for self-medication in children <6 years of age. a e f
Possible conjunctival irritation and adverse systemic effects (including marked sedation) associated with excessive dosage and/or prolonged or too frequent use. c
Geriatric Use:
Possible liberation of pigment granules, presumably from the iris following conjunctival application of naphazoline, especially high...